LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Vitamin Shoppe, Inc. (“Vitamin Shoppe” or the “Company”) (NYSE: VSI) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Vitamin Shoppe page on our website at www.glancylaw.com/case/vitamin-shoppe-inc.
On May 10, 2017, Vitamin Shoppe released poor first quarter 2017 financial results and slashed its fiscal 2017 guidance by 45%. However, the Company still claimed that its “reinvention plan” was succeeding. On this news, Vitamin Shoppe shares lost approximately one-third of their value, closing at $12.70 per share.
Then, on August 9, 2017, Vitamin Shoppe announced that it was taking a $168.1 million impairment charge relating to the Company’s retail segment, and that, as a result, Vitamin Shoppe would report a loss per share of $6.73. In addition, the Company dropped its fiscal 2017 earnings per share guidance altogether. On this news, Vitamin Shoppe’s common stock plunged again, falling $3.50 per share to close at $6.10 per share.
If you purchased Vitamin Shoppe securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.